Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | EML4 - ALK |
| Therapy | Ensartinib |
| Indication/Tumor Type | angiosarcoma |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| EML4 - ALK | angiosarcoma | predicted - sensitive | Ensartinib | Case Reports/Case Series | Actionable | In a clinical case study, Ensacove (ensartinib) treatment resulted in a partial regression in a patient with pulmonary epithelioid angiosarcoma harboring EML4-ALK (e13:e20) (PMID: 41836264). | 41836264 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (41836264) | A rare pulmonary epithelioid angiosarcoma with ALK rearrangement: a case report and literature review. | Full reference... |